Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | BUB1 | O43683 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30491246 | 0.83 | ELANE (0.37) | GPR119BCHEELANEPOLBL3MBTL1 | |
| SCHEMBL16593587 | 0.81 | L3MBTL1 (0.43) | GPR119BCHEELANEPOLBGABRG2 | |
| SCHEMBL16593256 | 0.79 | L3MBTL1 (0.34) | GPR119BCHEPOLBGABRG2GABRB3 | |
| SCHEMBL13386031 | 0.79 | MAPK1 (0.33) | BCHEELANEGABRG2GABRB3GABRA5 | |
| SCHEMBL30934733 | 0.79 | MAPK1 (0.33) | BCHEELANEGABRG2GABRB3GABRA5 | |
| SCHEMBL27924812 | 0.79 | ELANE (0.39) | ELANE | |
| SCHEMBL29631631 | 0.78 | ELANE (0.55) | GPR119ELANEPOLBL3MBTL1 | |
| SCHEMBL295518 | 0.78 | ELANE (0.55) | GPR119ELANEPOLBL3MBTL1 | |
| SCHEMBL16606149 | 0.78 | POLB (0.37) | GPR119BCHEPOLBGABRG2GABRB3 | |
| SCHEMBL16606153 | 0.77 | CFTR (0.37) | GPR119BCHEPOLBGABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635581-B1 | 7-([1,2,3]TRIAZOL-4-YL)-PYRROLO[2,3-B]PYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-25 | — | — | EP | disclosed |
| US-8865715-B2 | Substituted 7-(1,2,3-Triazol-4-yl)-pyrrolo[2,3-b]pyrazines | MERCK PATENT GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| US-8865715-B2 | Substituted 7-(1,2,3-Triazol-4-yl)-pyrrolo[2,3-b]pyrazines | MERCK PATENT GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| US-8865715-B2 | Substituted 7-(1,2,3-Triazol-4-yl)-pyrrolo[2,3-b]pyrazines | MERCK PATENT GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| US-20130217951-A1 | 7-(1,2,3-TRIAZOL-4-YL) PYRROLO [2,3-B] PYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| US-20130217951-A1 | 7-(1,2,3-TRIAZOL-4-YL) PYRROLO [2,3-B] PYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| US-20130217951-A1 | 7-(1,2,3-TRIAZOL-4-YL) PYRROLO [2,3-B] PYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| WO-2012059171-A1 | 7-([1,2,3]TRIAZOL-4-YL)-PYRROLO[2,3-B]PYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217951-A1 | 7-(1,2,3-TRIAZOL-4-YL) PYRROLO [2,3-B] PYRAZINE DERIVATIVES | PDK1, PDK2, PDK3 | GPR119 683/4885BCHE 4720/4885ELANE 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.